AUPH News and Press, Aurinia Pharmaceuticals Inc From 05/07/21

Gainers: Regional Health Properties (RHE) +39%, Auris Medical (EARS) +26%, Clene (CLNN) +25%, Pro-Dex (PDEX) +20%, Epizyme (EPZM) +17%.Losers: ChemoCentryx (CCXI) -59%, Orphazyme (ORPH) -30%, F-star Therapeutics (FSTX) -21%, Aur...

ChemoCentryx (CCXI) -49% after FDA panel split 9-9 on efficacy for Chemocentryx's vasculitis candidate avacopan and reports outcome of FDA’s expert panel meeting on avacopan.Orphazyme  (ORPH) -28% after arimoclomol flunks late-stage amyotrophic lateral sclerosi...

Aurinia Pharmaceuticals (AUPH) down 20% after-hours after announcing financial results for the first quarter ended March 31, 2021.Revenues were $0.9M and $30K for Q1 2021 and 2020, respectively. The increase was the result of the commercial sales of Lupkynis, which began in January ...

Aurinia Pharmaceuticals Inc. (AUPH) Q1 2021 Results Earnings Conference Call May 06, 2021, 5:00 pm ET Company Participants Glenn Schulman - Senior Vice President, Corporate Communications and Investor Relations Peter Greenleaf - Chief Executive Officer, Director Max Colao - Chief Commercial O...

Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) , an early commercial-stage biotech, are down by 17% in after-hours trading Thursday afternoon. The biotech's stock is cratering in response to the company's 2021 first-quarter earnings report released after the closing bell today. ...

Aurinia Pharma (AUPH): Q1 GAAP EPS of -$0.40 misses by $0.02.Revenue of $0.91M (+2175.0% Y/Y) misses by $2.12M.Shares -1.13%.Press Release For further details see: Aurinia Pharma EPS misses by $0.02, misses on revenue

- Quarter highlights include FDA approval, launch and early market penetration of LUPKYNIS™ as the first approved oral therapy for lupus nephritis (LN) - - Over 250 patient start forms received by the end of the first quarter - - Cash and cash equivalents, a...

Stealth BioTherapeutics (MITO) +58% after showcases data for Elamipretide.Luokung Technology Corp. (LKCO) +22% on announcing favorable ruling granting preliminary injunction.Nemaura Medical (NMRD) +23% on 200K sugarBEAT sensors order.American Shared Hospital Services (AMS) +28%...

Aurinia Pharmaceuticals (AUPH) rose 5.5% in premarket trading on some speculation about potential takeover interest.AstraZeneca (AZN), GlaxoSmithKline (GSK) are speculated to be interested in Aurinia, according to the London Times.Recall Jan. 25, Aurinia  shares jump on voclosp...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its first quarter 2021 financial results on Thursday, May 6, 2021, after the markets close. Aurinia’s management team will also host a conference call at 5:00...